EPISODE · Jul 22, 2026 · 21 MIN
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
from BioSpace · host BioSpace
Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.
Embed this episode
NOW PLAYING
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
0:00
21:20
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BioSpace?
This episode is 21 minutes long.
When was this BioSpace episode published?
This episode was published on July 22, 2026.
Can I download this BioSpace episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!